Neuland Laboratories' Q4FY25 Total Income at Rs.335.8 crore; EBITDA at Rs.58.2 crore

Neuland Laboratories Limited (NLL), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the fourth quarter & full year ended March 31, 2025. The company saw a marginal decrease in topline in FY25 as compared to FY24, which is reflected in terms of the decline in operating margins. However, these results are in line with the company's initial outlook at the start of the year. Neuland continues to invest for medium and long-term growth and expects its growth trajectory to resume in FY26. The CMS revenues of Rs. 637 crores were largely driven by molecules in the commercial segment. The peptide investment plan is on track and the company continues to garner more projects in this space. The company has molecules in its portfolio which are currently at the take-off stage.